Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

Not Recruiting

Trial ID: NCT01929408

Purpose

The purpose of this study is to compare treatment methods and outcomes of patients diagnosed with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

Official Title

Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study

Eligibility


Inclusion Criteria

Patients with new diagnoses of non-M3 AML or high-risk MDS, myeloproliferative neoplasms
(MPN), or myelofibrosis (MF) (showing 10% or more blasts in bone marrow) who:

   - Present for an AML-like treatment that could plausibly produce a complete remission
   (CR); for example intensive induction chemotherapy, low dose single agent
   chemotherapy, hypomethylation agent, or a similar therapy

   - Possibility to retrieve follow-up records from the collaborating institution or
   treating primary care physician

   - Patients with primary refractory or first relapse presenting for salvage chemotherapy
   will be allowed

   - Patients of 18 years of age or older, and are being treated by the adult AML service.

   - Able to speak and read English.

   - Willing and able to provide informed consent.

Exclusion Criteria

   - Patients of ≤17 years of age or who are 18 or older and receive treatment under the
   pediatric AML service.

   - Patients older than 80 years

   - Patients with <6 months projected survival due to active second malignancy or other
   medical problem.

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061

New Trial Alerts

Receive email alerts when trials open to patients.